Long-term results of Nivolumab + Cabozantinib in RCC

Published Date: 08 Mar 2023

The combination of first-line nivolumab and cabozantinib continues to outperform sunitinib in the treatment of patients with advanced renal cell carcinoma (RCC).

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Global inequalities found in cancer research funding

2.

FDA Approves Treosulfan as Part of AML/MDS Conditioning Regimen

3.

New Clues to Origin of T-Cell Lymphoma After CAR-T Therapy

4.

Congresswoman has cancer; the IRS is suing a controversial doctor; and caffeine and teenagers.

5.

Advanced breast cancer patients living longer thanks to improvements in treatment and care


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot